title: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
abstract: OBJECTIVE
  Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to compare the efficacy and safety of zoledronic acid and pamidronate for treating hypercalcemia of malignancy (HCM).
  
  
  METHODS
  Patients with moderate to severe HCM (corrected serum calcium [CSC] > or = 3.00 mmol/L [12.0 mg/dL]) were treated with a single dose of zoledronic acid (4 or 8 mg) via 5-minute infusion or pamidronate (90 mg) via 2-hour infusion. A protocol-specified pooled analysis of the two parallel trials was performed. Clinical end points included rate of complete response by day 10, response duration, and time to relapse.
  
  
  RESULTS
  Two hundred eighty-seven patients were randomized and evaluated for safety; 275 were evaluated for efficacy. Both doses of zoledronic acid were superior to pamidronate in the treatment of HCM. The complete response rates by day 10 were 88.4% (P = .002), 86.7% (P = .015), and 69.7% for zoledronic acid 4 mg and 8 mg and pamidronate 90 mg, respectively. Normalization of CSC occurred by day 4 in approximately 50% of patients treated with zoledronic acid and in only 33.3% of the pamidronate-treated patients. The median duration of complete response favored zoledronic acid 4 and 8 mg over pamidronate 90 mg with response durations of 32, 43, and 18 days, respectively.
  
  
  CONCLUSIONS
  Zoledronic acid is superior to pamidronate; 4 mg is the dose recommended for initial treatment of HCM and 8 mg for relapsed or refractory hypercalcemia.
authors.affiliation: Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada. pierre.major@hrcc.on.ca
authors.forename: P
authors.initials: P
authors.lastname: Major
authors.forename: A
authors.initials: A
authors.lastname: Lortholary
authors.forename: J
authors.initials: J
authors.lastname: Hon
authors.forename: E
authors.initials: E
authors.lastname: Abdi
authors.forename: G
authors.initials: G
authors.lastname: Mills
authors.forename: H D
authors.initials: HD
authors.lastname: Menssen
authors.forename: F
authors.initials: F
authors.lastname: Yunus
authors.forename: R
authors.initials: R
authors.lastname: Bell
authors.forename: J
authors.initials: J
authors.lastname: Body
authors.forename: E
authors.initials: E
authors.lastname: Quebe-Fehling
authors.forename: J
authors.initials: J
authors.lastname: Seaman
mesh_terms: D000328:Adult; D000368:Aged; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D000077268:Pamidronate; D016032:Randomized Controlled Trials as Topic; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate